Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.

Abstract

Eight patients with cutaneous T-cell lymphomas (6 patients with mycosis fungoides, 1 patient with Sézary's syndrome, 1 patient with low-grade malignant lymphoma, unclassified) were treated with TP-5, a synthetic pentapeptide having the same biologic activity as the thymic hormone thymopoietin. TP-5 was administered three times weekly at a dosage of 50 mg subcutaneously in 6 patients, 50 mg intravenously in 1 patient, and 100 mg subcutaneously in 1 patient. Clinical evaluation at the end of the trial disclosed improvement in 4 patients (2 patients with mycosis fungoides, 1 patient with Sézary's syndrome, 1 patient with low-grade malignant lymphoma, unclassified), deterioration in 3 patients with mycosis fungoides and no change in 1 patient with mycosis fungoides. As TP-5 evidently exerts some effect on cutaneous T-cell lymphomas, further investigations of its therapeutic potential in this group of diseases seem worthwhile.

• Authors: B Przybilla, G Burg, C Schmoeckel, O Braun-Falco
• Journal: Acta dermato-venereologica (Acta Derm Venereol) Vol. 63 Issue 6 Pg. 524-9 ( 1983) ISSN: 0001-5555 [Print] Sweden
• PMID: 6198843 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Hormones
• Peptide Fragments
• Thymopoietins
• Thymus Hormones
• Thymopentin

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Female
• Hormones (administration & dosage, therapeutic use)
• Humans
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Mycosis Fungoides (drug therapy)
• Peptide Fragments (administration & dosage, therapeutic use)
• Sezary Syndrome (drug therapy)
• Skin Neoplasms (drug therapy)
• T-Lymphocytes
• Thymopentin
• Thymopoietins (administration & dosage, therapeutic use)
• Thymus Hormones (therapeutic use)
• Time Factors